ArticleBMC genomics2024
Dengue virus surveillance in Nepal yields the first on-site whole genome sequences of isolates from the 2022 outbreak.
Article in BMC genomics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Genomic Evidence for Novel Introduction and Intra-Host Diversity of DENV-2 in Dar es Salaam, Tanzania.Viruses · 2026Article
- Tracing Dengue's Evolutionary and Phylogenetic Pathways.Current topics in microbiology and immunology · 2026Review
- Molecular epidemiology and evolutionary trends of dengue virus serotype-2 strains in Sri Lanka.BMC microbiology · 2025Article
- Diversity of dengue virus serotypes in Nepal during the 2022 outbreak.Tropical medicine and health · 2025Article
- Genomics in Epidemiology and Disease Surveillance: An Exploratory Analysis.Life (Basel, Switzerland) · 2025Review
- Elevated liver enzyme (AST and ALT) as biomarkers for severe dengue in Nepalese patients: a cross-sectional study.BMC infectious diseases · 2025Article
- Leukopenia and thrombocytopenia in dengue patients: a cross-sectional study from a tertiary hospitals in Koshi Province, Nepal.BMC infectious diseases · 2025Article
Corrections and comments
- Update of
Authors and funding
18 authors.
Funding
Abstract
backgroundThe 4 serotypes of dengue virus (DENV1-4) can each cause potentially deadly dengue disease, and are spreading globally from tropical and subtropical areas to more temperate ones. Nepal provides a microcosm of this global phenomenon, having met each of these grim benchmarks. To better understand DENV transmission dynamics and spread into new areas, we chose to study dengue in Nepal and, in so doing, to build the onsite infrastructure needed to manage future, larger studies. METHODS AND
resultsDuring the 2022 dengue season, we enrolled 384 patients presenting at a hospital in Kathmandu with dengue-like symptoms; 79% of the study participants had active or recent DENV infection (NS1 antigen and IgM). To identify circulating serotypes, we screened serum from 50 of the NS1
conclusionThese findings highlight DENV's geographic expansion from neighboring countries, identify China and India as the likely origin of the 2022 DENV cases in Nepal, and demonstrate the feasibility of building onsite capacity for more rapid genomic surveillance of circulating DENV. These ongoing efforts promise to protect populations in Nepal and beyond by informing the development and deployment of DENV drugs and vaccines in real time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.